NCT05248841 - A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions

Type 1 Diabetes MellitusType 2 Diabetes Mellitus

Interventions

DRUG

HEC-Glargine

Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.

DRUG

US-Lantus

Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.

Trial Locations (1)

FARMOVS Clinical Research Organization, Bloemfontein